If you have been reading about amino acid sequence and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Lyophilized powder storage | -20 C or colder, desiccated, protected from light | Long-term condition cited in supplier documentation |
| Reconstituted solution storage | 2-8 C for short-term use | Stability decreases after dissolution |
| Appearance | White to off-white lyophilized powder | Used as a visual identity check |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar organic solvents |
| Typical analytical method | Reversed-phase HPLC with UV detection at 214 nm | Purity estimate; mass spectrometry confirms molecular mass |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
=== No development reported === ACH-36 – undefined mechanism of action [22] Alprazolam sublingual – GABAA receptor positive allosteric modulator and benzodiazepine [23] Antalarmin (CP-154526) – corticotropin-releasing hormone (CRH) inhibitor [24] Buspirone controlled release (Buspirone ER) – serotonin 5-HT1A receptor partial agonist and other actions [25] BW-723C86 – serotonin 5-HT2B and 5-HT2C receptor agonist [26] Cannabidiol dry powder inhalation (RLS-103) – cannabinoid receptor modulator and other actions [27] Darigabat (CVL-865; PF-06372865; PF-6372865) – GABAA receptor positive allosteric modulator [28] Divaplon (RU-32698) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazolpyrimidine [29] Fananserin (RP-62203) – serotonin 5-HT2A receptor antagonist and dopamine D4 receptor antagonist [30] FR260010 (FR-260010) – serotonin 5-HT2C receptor antagonist [31] [32] GSK-588045 (GSK588045) – serotonin 5-HT1A, 5-HT1B, and 5-HT1D receptor antagonist [33] GSK-1360707 – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) [34] GT-001 – GABAA receptor positive allosteric modulator [35] Guanfacine extended release (Connexyn; Intuniv; Intuniv XR; S-877503; SHP-503; SPD-503) – α2-adrenergic receptor agonist [36] Itriglumide (CR-2945) – cholecystokinin B (CCKB) receptor antagonist [37] Lohocla-201 (Kindolor) – various actions [38] LY-293284 – serotonin 5-HT1A receptor agonist [39] NMRA-511 (BTRX-323511; NMRA-323511) – vasopressin V1A receptor antagonist [40] Paroxetine (Aropax; BRL-29060; Deroxat; Divarius; FG-7051; Frosinor; Motivan; NNC-207051; Paxil; Seroxat; SI-211103; Tagonis) – selective serotonin reuptake inhibitor (SSRI) [41] Psilocybin (MYCO-001; MYCO-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen [42] PT-00114 (PT100114) – corticotropin-releasing hormone (CRH) inhibitor [43] Research programme: allosteric modulators - Addex Therapeutics – various actions [44] Research programme: AMPA receptor agonists - RespireRx (ampakines; CX compounds) – AMPA receptor agonists and brain-derived neurotrophic factor (BDNF) stimulants [45] Research programme: anxiety and neurological disorder therapeutics - AstraZeneca – various actions [46] Research programme: cannabis-based therapeutics - Skye Bioscience – cannabinoid receptor agonists [47] Research programme: neuropeptide S receptor modulators - Pfizer (WYE-198232) – neuropeptide receptor agonists [48] Research programme: oxytocin receptor agonist - Wyeth – oxytocin receptor agonists [49] RGH-618 – metabotropic glutamate mGlu5 receptor negative allosteric modulator [50] Riluzole (PK-26124; Rilutek; RP-54274) – various actions [51] Risperidone (JNJ-410397-AAA; R-64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot) – atypical antipsychotic (non-selective monoamine receptor modulator) [52] Saripidem (SL-850274) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazopyridine [53] SB-242084 (SB242084) – serotonin 5-HT2C receptor antagonist [54] SRX-246 (API-246) – vasopressin V1A receptor antagonist [55] SYT-510 – anandamide reuptake inhibitor [56] Tebideutorexant (JNJ-3215; JNJ-61393215; Orexin-1) – orexin OX1 receptor antagonist [57] WAY-100135 – serotonin 5-HT1A receptor antagonist [58] Ziprasidone (CP-88059-01; CP-88059-1; Geodon; ME-2112; RQ-00000003; Zeldox) – atypical antipsychotic (non-selective monoamine receptor modulator) [59]
== Gene expression assays == Reporter genes can be used to assay for the expression of a gene of interest that is normally difficult to quantitatively assay. Reporter genes can produce a protein that has little obvious or immediate effect on the cell culture or organism. They are ideally not present in the native genome to be able to isolate reporter gene expression as a result of the gene of interest's expression. To activate reporter genes, they can be expressed constitutively, where they are directly attached to the gene of interest to create a gene fusion. This method is an example of using cis-acting elements where the two genes are under the same promoter elements and are transcribed into a single messenger RNA molecule. The mRNA is then translated into protein. It is important that both proteins be able to properly fold into their active conformations and interact with their substrates despite being fused. In building the DNA construct, a segment of DNA coding for a flexible polypeptide linker region is usually included so that the reporter and the gene product will only minimally interfere with one another. Reporter genes can also be expressed by induction during growth. In these cases, trans-acting elements, such as transcription factors are used to express the reporter gene. Reporter gene assay have been increasingly used in high throughput screening (HTS) to identify small molecule inhibitors and activators of protein targets and pathways for drug discovery and chemical biology. Because the reporter enzymes themselves (e.g.
=== Discovery of lysosome === Christian de Duve and his team continued studying the insulin mechanism-of-action in liver cells, focusing on the enzyme glucose 6-phosphatase, the key enzyme in sugar metabolism (glycolysis) and the target of insulin. They found that G6P was the principal enzyme in regulating blood sugar levels, but, they could not, even after repeated experiments, purify and isolate the enzyme from the cellular extracts. So they tried the more laborious procedure of cell fractionation to detect the enzyme activity. This was the moment of serendipitous discovery. To estimate the exact enzyme activity, the team adopted a procedure using a standardised enzyme acid phosphatase; but they were finding the activity was unexpectedly low—quite low, i.e., some 10% of the expected value. Then one day they measured the enzyme activity of some purified cell fractions that had been stored for five days. To their surprise the enzyme activity was increased back to that of the fresh sample; and similar results were replicated every time the procedure was repeated. This led to the hypothesis that some sort of barrier restricted rapid access of the enzyme to its substrate, so that the enzymes were able to diffuse only after a period of time. They described the barrier as membrane-like—a "saclike structure surrounded by a membrane and containing acid phosphatase." An unrelated enzyme (of the cell fractionation procedure) had come from membranous fractions that were known to be cell organelles. In 1955, de Duve named them "lysosomes" to reflect their digestive properties.
In 1925, the CCP's Central Military Department, was renamed the Central Military Commission. It was first led by Zhang Guotao who was replaced by Zhou Enlai in 1926 as head of the CMC. At the time of the First United Front, the CMC was not a unified military command structure but was more of an administrative liaison with other armed communist groups. The CCP founded its military wing on 1 August 1927 during the Nanchang uprising, beginning the Chinese Civil War. Communist elements of the National Revolutionary Army rebelled under the leadership of Zhu De, He Long, Ye Jianying, Zhou Enlai, and other leftist elements of the Kuomintang (KMT) after the Shanghai massacre in 1927. They were then known as the Chinese Workers' and Peasants' Red Army, or simply the Red Army. In 1934 and 1935, the Red Army survived several campaigns led against it by Chiang Kai-Shek's Kuomintang and engaged in the Long March. During the Second Sino-Japanese War from 1937 to 1945, the CCP's military forces were nominally integrated into the National Revolutionary Army of the Republic of China, forming two main units, the Eighth Route Army and the New Fourth Army. During this time, these two military groups primarily employed guerrilla tactics, generally avoiding large-scale battles with the Japanese, and at the same time consolidating by recruiting KMT troops and paramilitary forces behind Japanese lines into their forces.
Sources: en.wikipedia.org
== Further reading == Richardson, J. S. (1981). "The Anatomy and Taxonomy of Protein Structure". Anatomy and Taxonomy of Protein Structures. Advances in Protein Chemistry. Vol. 34. pp. 167–339. doi:10.1016/S0065-3233(08)60520-3. ISBN 978-0-12-034234-1. PMID 7020376., available on-line at Anatax Branden, C.-I.; Tooze, J. (1991), Introduction to Protein Structure, Garland Publishing, NY, ISBN 0-8153-0344-0 Arya, A (2026), Pearson Biochemistry: A Conceptual Approach, Pearson International, IN, ISBN 978-9-37-136081-4
Other causative conditions include infections, toxicities, antiphospholipid syndrome, cryoglobulinemia, neoplasms. In these cases, the observed cutaneous changes are known as "secondary acrocyanosis". They may have a less symmetric distribution and may be associated with pain and tissue loss.
== Function == The abundance and ubiquity indicate that TCTP may have important primary functions. However, a large number of cellular and biochemical functions have been found since 1980s. Most of these functions can be classified into three groups.
Sources: en.wikipedia.org
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.
Low temperature and low moisture slow hydrolysis and oxidation, the two main degradation routes for short peptides. A desiccant limits water uptake each time the vial is opened.
No single number captures identity, counter-ion content, water content, or sterility. A purity figure from one laboratory method reflects only what that method detects, and different methods can give different values for the same sample.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.